India
· Delayed Price · Currency is INR NSE: SPARC Statistics
Total Valuation
Sun Pharma Advanced Research Company has a market cap or net worth of INR 64.83 billion. The enterprise value is 65.78 billion.
| Market Cap | 64.83B |
| Enterprise Value | 65.78B |
Important Dates
The next estimated earnings date is Monday, February 3, 2025.
| Earnings Date | Feb 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Sun Pharma Advanced Research Company has 324.52 million shares outstanding. The number of shares has increased by 4.38% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 324.52M |
| Shares Change (YoY) | +4.38% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 25.64% |
| Owned by Institutions (%) | 6.45% |
| Float | 91.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 107.91 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.10 |
| EV / Sales | 109.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.19 |
Financial Position
The company has a current ratio of 0.32
| Current Ratio | 0.32 |
| Quick Ratio | 0.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.22 |
| Interest Coverage | -175.97 |
Financial Efficiency
Return on equity (ROE) is -321.41% and return on invested capital (ROIC) is -140.09%.
| Return on Equity (ROE) | -321.41% |
| Return on Assets (ROA) | -52.41% |
| Return on Capital (ROIC) | -140.09% |
| Revenue Per Employee | 1.47M |
| Profits Per Employee | -9.99M |
| Employee Count | 409 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.00% in the last 52 weeks. The beta is 0.85, so Sun Pharma Advanced Research Company's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | -23.00% |
| 50-Day Moving Average | 210.18 |
| 200-Day Moving Average | 244.77 |
| Relative Strength Index (RSI) | 39.98 |
| Average Volume (20 Days) | 1,810,134 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sun Pharma Advanced Research Company had revenue of INR 600.85 million and -4.09 billion in losses. Loss per share was -12.59.
| Revenue | 600.85M |
| Gross Profit | 224.47M |
| Operating Income | -4.14B |
| Pretax Income | -4.08B |
| Net Income | -4.09B |
| EBITDA | -4.05B |
| EBIT | -4.14B |
| Loss Per Share | -12.59 |
Balance Sheet
The company has 60.70 million in cash and 1.01 billion in debt, giving a net cash position of -951.40 million or -2.93 per share.
| Cash & Cash Equivalents | 60.70M |
| Total Debt | 1.01B |
| Net Cash | -951.40M |
| Net Cash Per Share | -2.93 |
| Equity (Book Value) | -773.80M |
| Book Value Per Share | -2.39 |
| Working Capital | -1.88B |
Cash Flow
In the last 12 months, operating cash flow was -4.38 billion and capital expenditures -250.38 million, giving a free cash flow of -4.63 billion.
| Operating Cash Flow | -4.38B |
| Capital Expenditures | -250.38M |
| Free Cash Flow | -4.63B |
| FCF Per Share | -14.28 |
Margins
| Gross Margin | 37.36% |
| Operating Margin | -689.60% |
| Pretax Margin | -678.59% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Sun Pharma Advanced Research Company does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.38% |
| Shareholder Yield | -4.38% |
| Earnings Yield | -6.30% |
| FCF Yield | -7.15% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |